Developer docs
API playgroundTry for free, no card

Search company profiles

Atea Pharmaceuticals

Full company profile

uuid0002hd3

Namestring
Atea Pharmaceuticals
Legal namestring
Atea Pharmaceuticals, Inc.
Websiteurl
ateapharma.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that discovers and develops oral direct-acting antiviral therapies targeting single-stranded RNA viruses, with current pipeline focus on hepatitis C (HCV) and hepatitis E (HEV). Its core technology is a proprietary purine nucleos(t)ide prodrug platform designed to inhibit viral RNA-dependent RNA polymerase; lead assets include the nucleotide analog polymerase inhibitor bemnifosbuvir (AT-511) and the NS5A inhibitor ruzasvir, formulated as a once-daily, protease-inhibitor-free fixed-dose combination for HCV, plus the investigational HEV candidate AT-587.

The company's technology differentiators include approximately 10-fold greater in vitro potency than sofosbuvir against HCV GT1-5, full activity against S282T resistance-associated substitutions, an 8-week treatment duration for non-cirrhotic patients, no food effect, and low drug-drug interaction risk with common co-medications. Bemnifosbuvir has been administered to over 2,300 subjects and ruzasvir to over 2,100 HCV-infected patients in trials to date. The platform is currently in global Phase 3 development, with the C-BEYOND (North America) and C-FORWARD (17 countries outside North America) trials each having enrolled over 880 patients, and topline data from C-FORWARD expected around year-end 2026.

Atea is pre-revenue with no approved products on the market; the company reported an annual net loss of $158.35 million against approximately $256 million in cash as of Q1 2026, providing runway through 2027. Capital has historically come from a $215 million Series D (May 2020, led by Bain Capital Life Sciences) and a $350 million upfront payment from a 2020 strategic collaboration with Roche for ex-U.S. rights to AT-527 in COVID-19. Future revenue is planned from commercialization of the bemnifosbuvir/ruzasvir regimen targeting the ~$2.5 billion global HCV therapeutics market, with leadership now being expanded via a Chief Commercial Officer to support an enterprise sales motion into healthcare-provider networks.

Short descriptiontext

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, with a lead HCV regimen (bemnifosbuvir plus ruzasvir) in global Phase 3 trials and an early-stage hepatitis E candidate, targeting patients with serious RNA viral infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antiviral therapeutics, hepatitis C treatment, oral direct-acting antivirals, nucleotide prodrug platform, clinical-stage biopharmaceutical
Industry3 codes
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antiviral Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-revenue clinical-stage operations
TypeSubscription Recurring
Description

Atea is currently a clinical-stage biopharmaceutical company with no commercial product revenue; reported an annual loss of $158.35 million and has not yet launched a product. Capital is sourced from equity financings (e.g., $215M Series D in 2020) and existing cash reserves of $256 million (Q1 2026) supporting runway through 2027.

defenseworld.net
2Future product sales (planned HCV regimen commercialization)
TypeOne Time License
Description

Future revenue expected from commercialization of bemnifosbuvir + ruzasvir fixed-dose combination for HCV, targeting a market with approximately $2.5 billion in 2025 global net sales (Mavyret/Epclusa and authorized generic).

ateapharma.com
3Licensing royalties (historical Roche collaboration)
TypeLicensing Royalties
Description

Under the October 2020 strategic collaboration with Roche for AT-527 (COVID-19), Atea received a $350 million upfront cash payment with the potential for future milestone payments and royalties on sales of AT-527 outside the United States.

ateapharma.com
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for severe human viral infections, anchored by a proprietary purine nucleos(t)ide prodrug platform. Its lead program is a once-daily, fixed-dose combination regimen of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) in global Phase 3 development for hepatitis C virus (HCV), with the AT-587 candidate advancing as a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV).

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Bemnifosbuvir + Ruzasvir Fixed-Dose Combination Regimen
CategoryAntiviral Therapeutics — Hepatitis C
Description

Oral once-daily, protease-inhibitor-free fixed-dose combination of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) being developed for the treatment of chronic hepatitis C virus (HCV) infection. Designed for 8-week (treatment-naïve non-cirrhotic) or 12-week (compensated cirrhotic) durations with no food effect and low drug-drug interaction risk, including with PPIs and statins. Targeted at hepatologists, infectious disease specialists, and HCV treatment networks globally.

2AT-587 (Investigational HEV Direct-Acting Antiviral)
CategoryAntiviral Therapeutics — Hepatitis E
Description

Investigational oral direct-acting antiviral being developed by Atea for the treatment of hepatitis E virus (HEV) infection. AT-587 has demonstrated 30- to 150-fold higher in vitro potency against HEV compared to sofosbuvir and ribavirin. Targeted at hepatologists and infectious disease specialists managing HEV-infected patients, including immunocompromised populations where no approved DAA currently exists.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atea Pharmaceuticals

Antiviral Pharmaceuticalsateapharma.com

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, with a lead HCV regimen (bemnifosbuvir plus ruzasvir) in global Phase 3 trials and an early-stage hepatitis E candidate, targeting patients with serious RNA viral infections.

What Atea Pharmaceuticals does

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that discovers and develops oral direct-acting antiviral therapies targeting single-stranded RNA viruses, with current pipeline focus on hepatitis C (HCV) and hepatitis E (HEV). Its core technology is a proprietary purine nucleos(t)ide prodrug platform designed to inhibit viral RNA-dependent RNA polymerase; lead assets include the nucleotide analog polymerase inhibitor bemnifosbuvir (AT-511) and the NS5A inhibitor ruzasvir, formulated as a once-daily, protease-inhibitor-free fixed-dose combination for HCV, plus the investigational HEV candidate AT-587.

The company's technology differentiators include approximately 10-fold greater in vitro potency than sofosbuvir against HCV GT1-5, full activity against S282T resistance-associated substitutions, an 8-week treatment duration for non-cirrhotic patients, no food effect, and low drug-drug interaction risk with common co-medications. Bemnifosbuvir has been administered to over 2,300 subjects and ruzasvir to over 2,100 HCV-infected patients in trials to date. The platform is currently in global Phase 3 development, with the C-BEYOND (North America) and C-FORWARD (17 countries outside North America) trials each having enrolled over 880 patients, and topline data from C-FORWARD expected around year-end 2026.

Atea is pre-revenue with no approved products on the market; the company reported an annual net loss of $158.35 million against approximately $256 million in cash as of Q1 2026, providing runway through 2027. Capital has historically come from a $215 million Series D (May 2020, led by Bain Capital Life Sciences) and a $350 million upfront payment from a 2020 strategic collaboration with Roche for ex-U.S. rights to AT-527 in COVID-19. Future revenue is planned from commercialization of the bemnifosbuvir/ruzasvir regimen targeting the ~$2.5 billion global HCV therapeutics market, with leadership now being expanded via a Chief Commercial Officer to support an enterprise sales motion into healthcare-provider networks.

Atea Pharmaceuticals firmographics

Firmographics
Name
Atea Pharmaceuticals
Legal name
Atea Pharmaceuticals, Inc.
Website
https://ateapharma.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, with a lead HCV regimen (bemnifosbuvir plus ruzasvir) in global Phase 3 trials and an early-stage hepatitis E candidate, targeting patients with serious RNA viral infections.
Ownership category
akta.pro rank

Atea Pharmaceuticals industry classification

Industry
Product category
Antiviral Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antiviral therapeutics
  • Hepatitis C treatment
  • Oral direct-acting antivirals
  • Nucleotide prodrug platform
  • Clinical-stage biopharmaceutical

Where Atea Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Atea Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pre-revenue clinical-stage operations: Atea is currently a clinical-stage biopharmaceutical company with no commercial product revenue; reported an annual loss of $158.35 million and has not yet launched a product. Capital is sourced from equity financings (e.g., $215M Series D in 2020) and existing cash reserves of $256 million (Q1 2026) supporting runway through 2027.
  2. Future product sales (planned HCV regimen commercialization): Future revenue expected from commercialization of bemnifosbuvir + ruzasvir fixed-dose combination for HCV, targeting a market with approximately $2.5 billion in 2025 global net sales (Mavyret/Epclusa and authorized generic).
  3. Licensing royalties (historical Roche collaboration): Under the October 2020 strategic collaboration with Roche for AT-527 (COVID-19), Atea received a $350 million upfront cash payment with the potential for future milestone payments and royalties on sales of AT-527 outside the United States.

Go-to-market motion2 records

Atea Pharmaceuticals product offering

Product offering

Core offering

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for severe human viral infections, anchored by a proprietary purine nucleos(t)ide prodrug platform. Its lead program is a once-daily, fixed-dose combination regimen of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) in global Phase 3 development for hepatitis C virus (HCV), with the AT-587 candidate advancing as a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV).

Differentiator

Problem solved

Functional benefit

Products and services

  • Bemnifosbuvir + Ruzasvir Fixed-Dose Combination Regimen Oral once-daily, protease-inhibitor-free fixed-dose combination of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) being developed for the treatment of chronic hepatitis C virus (HCV) infection. Designed for 8-week (treatment-naïve non-cirrhotic) or 12-week (compensated cirrhotic) durations with no food effect and low drug-drug interaction risk, including with PPIs and statins. Targeted at hepatologists, infectious disease specialists, and HCV treatment networks globally.
  • AT-587 (Investigational HEV Direct-Acting Antiviral) Investigational oral direct-acting antiviral being developed by Atea for the treatment of hepatitis E virus (HEV) infection. AT-587 has demonstrated 30- to 150-fold higher in vitro potency against HEV compared to sofosbuvir and ribavirin. Targeted at hepatologists and infectious disease specialists managing HEV-infected patients, including immunocompromised populations where no approved DAA currently exists.

Companies that use Atea Pharmaceuticals

Customer profile

Ideal customer profiles2 records

Atea Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Atea Pharmaceuticals partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Atea Pharmaceuticals competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Atea Pharmaceuticals social profiles

Digital presence

Atea Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atea Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Atea Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atea Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atea Pharmaceuticals

What does Atea Pharmaceuticals do?

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for severe human viral infections, anchored by a proprietary purine nucleos(t)ide prodrug platform. Its lead program is a once-daily, fixed-dose combination regimen of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) in global Phase 3 development for hepatitis C virus (HCV), with the AT-587 candidate advancing as a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV).

Is Atea Pharmaceuticals a public or private company?

Atea Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Atea Pharmaceuticals founded?

Atea Pharmaceuticals was founded in 2014. It employs 51 to 100 people.

Where is Atea Pharmaceuticals based?

Atea Pharmaceuticals is headquartered in Boston, United States, in the North America region.

How does Atea Pharmaceuticals make money?

Three revenue lines are on record. Pre-revenue clinical-stage operations are the primary driver. The others are future product sales (planned HCV regimen commercialization) and licensing royalties (historical Roche collaboration).

Does Atea Pharmaceuticals have an API?

No public API is recorded for Atea Pharmaceuticals.

What industry is Atea Pharmaceuticals in?

Atea Pharmaceuticals's product category is Antiviral Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaAtea outlines runway into mid-2028 with $200M Hercules facility as it targets mid-2027 HCV NDA (NASDAQ:AVIR)Atea Pharmaceuticals outlined a runway into mid-2028, citing a $200M Hercules facility and Q3 2026 pipeline progress. The company targets a mid-2027 HCV NDA, with CEO Jean-Pierre Sommadossi noting significant progress across the pipeline.The Motley FoolAtea Pharma (AVIR) Q3 2026 Earnings Call TranscriptAtea Pharmaceuticals reported positive Phase 3 results for its BEM/RZR HCV regimen, achieving a 94% SVR rate in non-cirrhotic patients versus 95% for standard-of-care. The company secured a $200 million credit facility and maintains a cash runway through mid-2028. It plans to submit an NDA for mid-2027 and advance its HEV program toward proof-of-concept in 2027.Quiver QuantitativeAtea Reports $32.2 Million Third-Quarter Loss as HCV Trial Advances | AVIR Stock NewsAtea Pharmaceuticals reported a Q3 2026 net loss of $32.2 million, or $0.40 per share, with $191.2 million in cash. The company announced positive Phase 3 C-BEYOND results for its HCV regimen, with Phase 3 C-FORWARD topline expected in early 2027.Business & FinancialAtea Pharmaceuticals Secures Credit Facility For Up To $200 Million From Hercules CapitalAtea Pharmaceuticals secured a credit facility from Hercules Capital for up to $200 million, receiving $65 million at closing. The company expects topline results from its second Phase 3 trial, C-FORWARD, in early 2027 and an NDA submission in mid-2027. The financing aims to support its goal of a US launch of BEM/RZR in 2028.Business & FinancialAtea Pharmaceuticals Reports Third Quarter 2026 Financial Results And Provides Business UpdateAtea Pharmaceuticals reported a Q3 2026 net loss of $32.2 million, with cash and equivalents of $191.2 million. The company's Phase 3 program for HCV treatment is evaluating BEM/RZR, with over 1,760 patients enrolled. A conference call will be held to discuss results.American Banking and Market NewsAtea Pharmaceuticals (AVIR) Projected to Announce Earnings on MondayAtea Pharmaceuticals is projected to announce Q3 2026 earnings after market close on November 9th, with analysts expecting a loss of $0.51 per share and revenue of $50.45 million. The company's stock has a consensus 'Hold' rating with a price target of $7.00, and its lead product candidate is bemnifosbuvir for COVID-19.Business & FinancialAtea Pharmaceuticals To Host Third Quarter 2026 Financial Results And Business Update Conference Call On November 9, 2026Atea Pharmaceuticals will host its third-quarter 2026 financial results and business update conference call on November 9, 2026. Participants can register for the live call, with a webcast available on the company's investor relations page. An audio archive will be posted within two hours and remain for 90 days.MarketBeatAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Shorted: Short Interest Down 61.1% in OctoberAtea Pharmaceuticals' short interest fell 61.1% in October to 3,070,296 shares, with 4.9% of shares sold short. Analysts have a consensus 'Hold' rating and a $7.00 price target, while the stock opened at $4.27. The company reported a quarterly loss of $0.41 per share, beating estimates.Seeking AlphaAtea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAtea Pharmaceuticals presented at Morgan Stanley's conference, reporting a successful Phase III trial for its hepatitis C treatment. The trial achieved the FDA-agreed primary endpoint on SVR12 with non-inferiority to Epclusa, and the company believes its regimen is best-in-class with short duration.Markets DailyAtea Pharmaceuticals (NASDAQ:AVIR) Raised to Hold at Wall Street ZenWall Street Zen upgraded Atea Pharmaceuticals from Sell to Hold, while Morgan Stanley raised its price target to $7.00. The stock has an average rating of Hold with a consensus target of $7.00, and the company reported a loss of $0.41 per share for the quarter.